Warfarin therapy
185 results
1 - 100Warfarin therapy
- Essentials
- Indications for warfarin therapy
- Complications
- References
- Contraindications to warfarin therapy
- Initiation and intensity of warfarin therapy
- INR determinations
- Interactions
- Duration of the treatment
- Pregnancy and breastfeeding
- Temporary reduction of warfarin dose; bridging therapy
- Thrombosis despite warfarin therapy
Don't add aspirin to warfarin therapy except with mechanical heart valve
Discontinuing warfarin therapy indefinitely after GI bleeding assoc with worse outcomes
Warfarin or antiplatelet therapy for stroke prevention in patients with non-valvular atrial fibrillation
Continued warfarin better than bridging therapy for pacemaker or defibrillator surgery (BRUISE CONTROL)
Antithrombotic agents in primary health care
NOAC versus warfarin post‐PCI in atrial fibrillation
Indications for and implementation of anticoagulant therapy in atrial fibrillation
Benefits to resuming warfarin in patients with atrial fibrillation after intracranial bleeds
Warfarin can safely be held for the short term
6 months of warfarin after aortic valve replacement reduces risk of CV death
Vitamins
Warfarin superior to antiplatelet treatment for A Fib
Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review
Many patients using warfarin also take aspirin
Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
Warfarin: damned if you do, damned if you don't
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Percutaneous left atrial appendage closure reduces AF stroke risk
More harm than good with bridge therapy in low-risk VTE patients
Heart valve operation: patient follow-up and complications
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease New
Genetic information does not add benefit to a clinical algorithm for warfarin management
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm Edited (no change to conclusions)
Dabigatran reduces risk of stroke and embolism in patients with AF
Bleeding risk with warfarin high among elderly, especially older than 80
Optimal loading dose of warfarin for the initiation of oral anticoagulation Stable (no update expected for reasons given in 'What's new')
Clinically significant bleeding occurs in 3.8% per year of pts aged 65+ years using warfarin
Anticoagulation for heart failure in sinus rhythm
Prevention of venous thromboembolism
Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
Mitral regurgitation
Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
Genotype-guided perioperative warfarin dosing may not be superior to algorithm-guided dosing
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
Aortic stenosis
Assessment and treatment of a patient with bleeding diathesis
Rivaroxaban similar to warfarin for patients with NVAF
Vitamin K for improved anticoagulation control in patients receiving warfarin
NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
Oral anticoagulation for prolonging survival in patients with cancer
Vitamin K for improved anticoagulation control in patients receiving warfarin: Cochrane systematic review
Closure of PFO similar to medical therapy for cryptogenic stroke or TIA
Clopidogrel + ASA for afib: fewer strokes, more hemorrhages (ACTIVE)
Joint injection okay in anticoagulated patients
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation Edited (no change to conclusions), comment added to review
Anticoagulation versus placebo for heart failure in sinus rhythm Edited (no change to conclusions)
Anticoagulation reversal with vitamin K doesn't reduce bleeding
Treatment approach for atrial fibrillation: rate control or rhythm control?
Dabigatran cost-effective for AF prophylaxis in some patients, not others
Rivaroxaban effective for acute DVT (EINSTEIN)
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome New search for studies and content updated (conclusions changed)
Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack: Cochrane systematic review
Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks Edited (no change to conclusions)
Coumadin + aspirin no better than aspirin alone for PAD
Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy: Cochrane systematic review
Transient ischaemic attack (TIA)
Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack: Cochrane systematic review
Resuming oral anticoagulants after a bleed is associated with fewer thrombi and deaths, but more bleeds
Systemic lupus erythematosus (SLE)
Lumbar puncture
Fungal infections of the mouth